Author(s)

M. C. O. Ezeibe^1*, B. L. Salako², F. I. O. Onyeachonam¹, A. David², O. O. Aina², E. Herbertson², M. E. Sanda¹, I. J. Ogbonna¹, E. Kalu¹, N. U. Njoku¹, M. I. Udobi¹, C. A. Akpan¹

¹College of Veterinary Medicine, Michael Okpara University of Agriculture, Umudike, Nigeria.
²Nigerian Institute of Medical Research, Lagos, Nigeria.

In verifying antiretroviral efficacy of a Nigerian broad spectrum antiviral medicine (Antivirt^®), the Nigerian Institute of Medical Research certified it safe by toxicological test on laboratory animals, before commencing treatment of three HIV/AIDS patients whose viral loads varied widely (millions, hundreds of thousands and thousands). To overcome errors associated with such wide differences in subject-classes, percentages of viral load-reductions were calculated instead of comparing their viral loads. After first month of the Antivirt^®-treatment, means of ranked viral loads of the patients significantly (P ≤ 0.05) increased from 10.00 ± 7.21 to 11.30 ± 5.51 (-41.03% infection-reduction rate) instead of reducing. From second month of the trial, their viral loads started to reduce, continuously, so that their infection-reduction rates have been increasing from that -41.03%, to -38.22% in the second month; 23.98% in the third month; 31.76% in the fourth month and 64.12% after the fifth month.

Antivirt^®, Opposite Charges’ Electrostatic Attraction, Continuous Depletion Of HIV-Infection Loads

Ezeibe, M. , Salako, B. , Onyeachonam, F. , David, A. , Aina, O. , Herbertson, E. , Sanda, M. , Ogbonna, I. , Kalu, E. , Njoku, N. , Udobi, M. and Akpan, C. (2020) HIV-Infection Reduction-Rates in Patients, on Antiretroviral Efficacy-Trial of a Nigerian Broad-Spectrum Antiviral Medicine (Antivirt^®). World Journal of AIDS, 10, 141-148. doi: 10.4236/wja.2020.102012.